% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Albers:302890,
      author       = {P. Albers$^*$ and A. Krilaviciute$^*$ and P. Seibold$^*$
                      and M. de Vrieze$^*$ and J. Lakes and M. A. Kuczyk and N. N.
                      Harke and J. Debus and C. A. Grott and J. E. Gschwend and K.
                      Herkommer and V. A. Soehne and A. Benner$^*$ and G.
                      Kristiansen and B. Hadaschik and C. Arsov and G. Antoch and
                      L. Schimmöller and F. L. Giesel and M. R. Makowski and F.
                      Wacker and H.-P. Schlemmer$^*$ and R. Kaaks$^*$ and N.
                      Becker$^*$},
      title        = {{D}o {W}e {N}eed {E}arly {D}etection of {G}rade {G}roup 2
                      {P}rostate {C}ancer in a {S}creening {P}rogram for {Y}oung
                      {M}en? {R}esults from the {PROBASE} {S}creening {T}rial.},
      journal      = {European urology oncology},
      volume       = {nn},
      issn         = {2588-9311},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-01430},
      pages        = {nn},
      year         = {2025},
      note         = {#EA:C130#LA:C130# / epub},
      abstract     = {In general, low-risk and favorable intermediate-risk
                      prostate cancers (PCs; International Society of Urological
                      Pathology grade group [GG] 1 and GG 2) are slow-growing
                      cancers with low metastatic potential. Active surveillance
                      is recommended for GG 1 PC and can be recommended for GG 2
                      PC in the absence of adverse pathological parameters.
                      Therefore, the question arises as to when low-grade PC
                      should be detected in a screening setting. We conducted an
                      analysis of the group with intermediate prostate-specific
                      antigen (PSA) risk (1.5-2.99 ng/ml) from the PROBASE
                      screening trial for young men (starting age 45 yr) and
                      evaluated 159 biopsies performed for confirmed PSA ≥3
                      ng/ml in the first two biennial screening rounds. Of these
                      biopsies, $37\%$ were positive, with $78\%$ (46/59) showing
                      GG 1 or GG 2 disease. Only $0.8\%$ of men with intermediate
                      risk (13 of 1661 men screened) had GG 3-5 PC and would have
                      experienced a delay in diagnosis of between 1 and 3 yr if
                      screening were performed at 5-yr intervals. These results
                      suggest that the screening interval could be extended from 2
                      yr to 5 yr for men aged 45 yr at intermediate risk, similar
                      to the interval for men at low risk (PSA <1.5 ng/ml). This
                      would reduce unnecessary testing and overdiagnosis in nearly
                      $10\%$ of the screening population aged 45 yr.},
      keywords     = {Grade group (Other) / Intermediate risk (Other) /
                      International Society of Urological Pathology (Other) /
                      Prostate cancer (Other) / Screening (Other)},
      cin          = {C130 / C060 / E010 / C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C130-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)E010-20160331 / I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40640052},
      doi          = {10.1016/j.euo.2025.06.007},
      url          = {https://inrepo02.dkfz.de/record/302890},
}